SQZ eAPC HPV
Alternative Names: SQZ-eAPC-HPVLatest Information Update: 04 Mar 2024
Price :
$50 *
At a glance
- Originator SQZ Biotech
- Class Antineoplastics; Cancer vaccines; Cell therapies; Immunotherapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 27 Nov 2023 SQZ Biotech terminates the phase-I/II COMMANDER-001 trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy, Second-line therapy or greater) in USA due to the corporate decision made by the company (NCT05357898)
- 03 Nov 2023 Efficacy and adverse events data from the phase I/II COMMANDER-001 trial in Solid tumours released by SQZ Biotech
- 06 Dec 2022 SQZ eAPC HPV receives Fast Track designation for Solid tumours [Parenteral] (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, Treatment-experienced) in USA